Foundayo: What UK Patients Need to Know About the New Weight Loss Pill

Foundayo is a new FDA-approved weight loss pill gaining popularity among people who need medical weight loss support. It's a once-daily tablet containing orforglipron. Foundayo is approved in the US, but it's not yet available as a UK-licensed treatment.

This guide explains how it works, the average weight loss you can expect on the drug, side effects, and when it will be available in the UK. You'll also learn how it compares with other weight loss medications.

Key Takeaways

• Foundayo (orforglipron) is a once-daily GLP-1 weight loss pill approved in the US, but not yet available in the UK.
• It works by mimicking a natural hormone that helps regulate appetite, food intake, and blood sugar.
• Clinical trials showed an average weight loss of up to 12.4% at the highest dose, though results vary.
• Patients must use Foundayo alongside a reduced-calorie diet and lifestyle changes, under medical supervision.
• UK patients should consider approved alternatives like Mounjaro, Wegovy, or Saxenda through licensed providers such as Curely.

What Is Foundayo?

Foundayo or orforglipron is a GLP-1 receptor agonist taken as a daily tablet for chronic weight management in adults.

This weight loss pill helps regulate appetite, food intake, and blood sugar. Foundayo can help you feel fuller for longer, which may make it easier to eat less, leading to lower body weight.

The FDA approved Foundayo to treat adults with obesity or adults who are overweight and have weight-related health conditions in the US. Patients must use the weight loss medication with a reduced calorie diet and increased physical activity.

What Makes Foundayo Different?

The main difference between Foundayo and many current GLP-1 weight-loss treatments is the format. Mounjaro, Wegovy, and Saxenda are weight loss injections, while Foundayo is a tablet.

While there is a Wegovy pill (Rybelsus) in the US, the differences in how to take Foundayo can make it easier for some people. You must take Wegovy on an empty stomach with a 30-minute wait before eating or drinking. On the other hand, you can take Foundayo at any time of day, with or without food or water.

How Does Foundayo Work?

As a GLP-1 receptor agonist, Foundayo mimics a natural hormone released in the body that regulates blood sugar levels, fullness, and digestion.

When GLP-1 activity increases, your body may respond by:

• Feeling fuller after eating
• Experiencing fewer hunger signals
• Reducing portion sizes more comfortably
• Having steadier blood sugar levels

This does not mean that people taking Foundayo or any other FDA-approved weight-loss pills automatically lose weight. Results still depend on factors such as your dose, medical history, lifestyle, and how well you tolerate treatment.

How Much Weight Can You Lose on Foundayo?

[Photo by pixelshot on Canva.]

The ATTAIN-1 Phase 3 clinical trial had adults with obesity or overweight take orforglipron for 72 weeks alongside lifestyle support. Eli Lilly reported that people taking the highest dose lost an average of 12.4 kg (12.4% of body weight) at 72 weeks. The placebo group did not lose as much weight.

Foundayo is approved in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg, which is the highest dose in the approved US label.

Some people lost more weight than the average, while others lost less. That's normal with obesity medicine because your response depends on factors such as appetite, genetics, sleep, physical activity, medical conditions, and other medications.

Foundayo Eligibility

Adults must meet one of the following two categories to use Foundayo for excess body weight management:

• Obesity: A body mass index (BMI) of 30 kg/m² or higher.
• Overweight with Comorbidities: A BMI of 27 kg/m² or higher, plus at least one weight-related medical condition, such as hypertension, Type 2 diabetes, high cholesterol, obstructive sleep apnoea, or cardiovascular disease.

Even if you qualify, you must use GLP-1 weight-loss medication under clinical supervision. The right prescriber should first check whether the treatment is suitable for you by reviewing your medical conditions.

They should also explain the side effects and help you make changes if your symptoms become difficult to manage.

Who May Not Be Suitable

The US label includes a boxed warning about the risk of thyroid tumours. People with a personal or family history of medullary thyroid cancer should not use Foundayo. They may have serious side effects, including possible thyroid tumours. The same applies to people with Multiple Endocrine Neoplasia syndrome type 2.

You should also speak to a healthcare professional before taking any GLP-1 medication if you:

• Are pregnant, planning a pregnancy, or breastfeeding
• Take insulin or medicines that affect blood sugar control or levels
• Use birth control pills
• Take over-the-counter medicines or herbal supplements
• Have a history of pancreatitis, gallbladder disease, or severe stomach problems
• Have obstructive sleep apnoea or other weight related medical problems

There may also be guidance around contraception, including using a barrier method in some circumstances. Medicines that affect digestion may affect how your body absorbs birth control.

How to Take Foundayo

Patients take Foundayo as a daily pill, rather than a weekly injection or other non-oral form of GLP-1 medication. According to US prescribing guidance, patients can take it with or without food.

Treatment usually starts at the lowest dose and gradually increases. This helps your body adjust and reduces the chance of digestive side effects.

Patients go through a gradual dose increase over several weeks. A healthcare professional will decide the right amount based on response and tolerance. They may track:

• Changes in body weight
• Waist circumference, which reflects fat distribution
• Blood sugar levels
• Side effects

Diet and Lifestyle Guidance

Foundayo is not a standalone solution. It supports weight loss with a reduced-calorie diet and regular exercise. A practical dietary approach when using Foundayo includes:

• Prioritising protein to help maintain muscle mass
• Eating fibre-rich foods to support digestion
• Reducing highly processed, high-sugar foods
• Staying hydrated

The Cost of Foundayo

[Photo by Vlad Fratila on Canva.]

According to Eli Lilly, the cost of Foundayo starts at $149 per month for the 0.8mg dose. Other doses cost:

• 2.5mg dose starting at $199/month
• 5.5mg dose starting at $299/month
• 9mg, 14.5mg, and 17.2mg doses starting at $299/month, each

Insurance plans and the pharmacy provider can affect this pricing.

At the moment, Foundayo is not approved for use in the UK, so there's no official UK pricing. Even if Foundayo receives regulatory approval in the future, UK pricing may differ from the US due to:

• NHS and private prescribing frameworks
• Decisions by the National Institute for Health and Care Excellence
• Market competition from existing GLP 1 medications

Foundayo Side Effects and Safety Considerations

Foundayo can cause side effects, which include:

• Nausea
• Constipation
• Diarrhoea
• Vomiting
• Indigestion
• Abdominal pain
• Headache
• Bloating
• Fatigue
• Reflux
• Hair loss

These side effects are normal, especially when starting Foundayo or after a dose increase.

Serious Warnings and Precautions

• Pancreatitis: Characterised by severe abdominal pain that radiates to the back and doesn't go away.
• Gallbladder Disease: Rapid weight loss (and the medication's effect on bile) can lead to gallstones or inflammation of the gallbladder (cholecystitis).
• Low Blood Sugar: Foundayo can affect insulin and blood sugar levels. This risk is much higher if someone is also taking other diabetes medications such as insulin or sulfonylureas.
• Allergic Reactions: Swelling of the face, lips, or tongue, plus hives, or difficulty breathing.
• Kidney Problems: The medication doesn't hurt the kidneys directly, but severe vomiting or diarrhoea can lead to acute kidney injury due to fluid loss.

Seek urgent medical help if you develop severe pain in your stomach area, symptoms of a serious allergic reaction, trouble swallowing, breathing difficulty, or signs of dehydration.

Is Foundayo Available in the UK?

Foundayo is not currently available as a UK-licensed weight loss treatment. Medicines usually need authorisation from the Medicines and Healthcare Products Regulatory Agency for UK availability. The National Institute for Health and Care Excellence (NICE) may also assess treatments for NHS use.

At the time of writing, UK patients cannot access approved Foundayo through a UK pharmacy. Be cautious of any website that claims to sell Foundayo (orforglipron) in the UK without clear licensing information.

What UK Patients Can Do Now

There are other approved medications in the UK that help people lose weight. Speak to a UK-registered prescriber such as Curely for approved weight loss treatments.

Foundayo vs Mounjaro, Wegovy, and Saxenda

While these treatments help reduce excess body weight through hormone regulation, there are some key differences. Below is a comparison table of these medications in the UK:

The biggest differences are availability and weight loss results.

Treatments like Mounjaro, Wegovy injection, and Saxenda are the main regulated options for weight management in the UK. You can also find prescription weight loss pills such as Orlistat and over-the-counter options like Alli.

How Curely Supports Your Weight Loss Journey

Curely offers approved and regulated treatments that support weight loss in the UK. And you don't need an in-person GP appointment. Instead, we have a simple process that starts with a short online consultation. This helps check whether treatment is suitable for you.

If you're eligible for treatment, Curely’s clinicians can recommend suitable options and guide dosing, side effects, and ongoing use.

We deliver your treatment discreetly, with no branding on the packaging or bills. Curely also focuses on flexible care, so your plan can adapt if your needs change.

Start your weight loss journey through safe UK-licensed treatments today with Curely.

FAQs

Which is Better, Ozempic or Foundayo?

Ozempic and Foundayo are different medicines. Ozempic contains semaglutide, and doctors primarily use it to treat type 2 diabetes. Foundayo contains orforglipron and has been approved in the US for chronic weight management.

What Is the Most Successful Weight Loss Pill In the UK?

Orlistat is a popular weight-loss pill in the UK, which provides an average weight loss of 3-5%. Injectable GLP-1 treatments often produce greater average weight loss in clinical trial data. Foundayo is a GLP-1 pill, but it's not yet available as a UK-licensed option.

Is Foundayo Available In the UK?

No. Foundayo is FDA-approved in the US, but it is not currently accessible as a UK-licensed treatment. UK patients should avoid websites selling unregulated Foundayo (orforglipron). Speak with Curely about safe, approved alternatives.

What can I Use Instead of Foundayo in the UK?

Depending on your health and eligibility, options may include Mounjaro, Wegovy, or Saxenda. Start your consultation with Curely to find the most suitable treatment for you.

Conclusion

Foundayo is a promising oral GLP-1 weight loss pill, especially for people who would prefer tablets over injections. Clinical trials showed meaningful average weight loss. Also, there are no food or water restrictions, making it convenient for some patients.

However, Foundayo is not currently available as a UK-licensed treatment. Focus on safe, regulated options if you want medicated weight loss support now. Curely can help you compare current treatments, check your eligibility, and give clinical support.

References

• Lilly. “FDA Approves Lilly’s FoundayoTM (Orforglipron), the Only GLP-1 Pill for Weight Loss That Can Be Taken Any Time of Day without Food or Water Restrictions | Eli Lilly and Company.” Eli Lilly and Company, 2025.
• Office. “FDA Approves First New Molecular Entity under National Priority Voucher Program.” US Food and Drug Administration, 2026.
• Wharton, Sean, et al. “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.” New England Journal of Medicine, vol. 393, no. 18, 16 Sept. 2025.